Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-18 eCollection Date: 2020-09-01 DOI:10.1097/XCE.0000000000000206
Nathan D Wong
{"title":"Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?","authors":"Nathan D Wong","doi":"10.1097/XCE.0000000000000206","DOIUrl":null,"url":null,"abstract":"While we have seen great reductions in cardiovascular disease (CVD) morbidity and mortality over the past few decades, the rate of these declines has recently diminished, and there is even evidence that CVD mortality may be on the rise once again [1]. Much of this is fueled by the epidemic of obesity, metabolic syndrome and type 2 diabetes [2]. There is a wealth of evidence regarding the efficacy of cholesterol-lowering medications (particularly statins), blood pressure control, and most recently the treatment of diabetes with newer medications that positively impact CVD outcomes [2]. Yet recent data continue to demonstrate inadequate adherence to preventive medications and inadequate control of risk factors [3,4]. Even in the case of diabetes, where CVD is the major cause of morbidity and mortality, while many patients are at reasonable targets for HbA1c, blood pressure, and low-density lipoprotein-cholesterol individually, 20% or fewer are at all three targets simultaneously, suggesting a lack of coordinated care and understanding of the priorities that should be placed to reduce CVD risk in such persons [5]. Moreover, there is a continued rise in obesity both in developing and developed nations, with this closely linked to other cardiometabolic risk factors such as blood pressure and dyslipidemia, as well as being a strong determinant of type 2 diabetes. Consequently, there is an urgency for healthcare providers from different specialties to come together to address together the CVD risks common in many patients if we are to reduce, or at least prevent an imminent rise in CVD morbidity and mortality moving forward. While clearly there has been great progress made in the treatment of persons with known CVD, if we are to make further progress in the next few decades, there needs to be a shift in focus in cardiovascular medicine towards promoting cardiovascular health and prevention. A specialized field of preventive cardiology or cardiometabolic medicine [2] is meant to address this need.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000206","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XCE.0000000000000206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 2

Abstract

While we have seen great reductions in cardiovascular disease (CVD) morbidity and mortality over the past few decades, the rate of these declines has recently diminished, and there is even evidence that CVD mortality may be on the rise once again [1]. Much of this is fueled by the epidemic of obesity, metabolic syndrome and type 2 diabetes [2]. There is a wealth of evidence regarding the efficacy of cholesterol-lowering medications (particularly statins), blood pressure control, and most recently the treatment of diabetes with newer medications that positively impact CVD outcomes [2]. Yet recent data continue to demonstrate inadequate adherence to preventive medications and inadequate control of risk factors [3,4]. Even in the case of diabetes, where CVD is the major cause of morbidity and mortality, while many patients are at reasonable targets for HbA1c, blood pressure, and low-density lipoprotein-cholesterol individually, 20% or fewer are at all three targets simultaneously, suggesting a lack of coordinated care and understanding of the priorities that should be placed to reduce CVD risk in such persons [5]. Moreover, there is a continued rise in obesity both in developing and developed nations, with this closely linked to other cardiometabolic risk factors such as blood pressure and dyslipidemia, as well as being a strong determinant of type 2 diabetes. Consequently, there is an urgency for healthcare providers from different specialties to come together to address together the CVD risks common in many patients if we are to reduce, or at least prevent an imminent rise in CVD morbidity and mortality moving forward. While clearly there has been great progress made in the treatment of persons with known CVD, if we are to make further progress in the next few decades, there needs to be a shift in focus in cardiovascular medicine towards promoting cardiovascular health and prevention. A specialized field of preventive cardiology or cardiometabolic medicine [2] is meant to address this need.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预防心脏病学还是心脏代谢医学:一个新兴的亚专科?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Endocrinology & Metabolism
Cardiovascular Endocrinology & Metabolism CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.60
自引率
0.00%
发文量
24
期刊最新文献
Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Development of acute kidney injury following repair of Stanford type A aortic dissection is associated with increased mortality and complications: a systematic review, meta-analysis, and meta-regression analysis. The link between the risk of cardiovascular diseases and the intake of different types of dietary carbohydrates in Iranian adults. The lifetime healthcare costs of female obesity: modeling of England data and the costs of current pharmacotherapy. The evolving role of GLP-1 agonists in ischemic stroke prevention in diabetic patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1